ProfileGDS5678 / 1441871_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 61% 61% 56% 62% 59% 59% 63% 61% 61% 67% 61% 59% 61% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.69261
GSM967853U87-EV human glioblastoma xenograft - Control 23.6260661
GSM967854U87-EV human glioblastoma xenograft - Control 33.6233361
GSM967855U87-EV human glioblastoma xenograft - Control 43.3660856
GSM967856U87-EV human glioblastoma xenograft - Control 53.6360362
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6404659
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6261659
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7837363
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6189361
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.625661
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0618967
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6204261
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5393359
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6291761